Shenbagamoorthy Sundarraj
Research Subjects
Shenbagamoorthy Sundarraj has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Soundarapandian Kannan
Department of Zoology, School of Life Sciences, Periyar University, Salem, India
9 shared publications Mohanan V. Sujitha
Cancer Biology Lab, Centre for Molecular and Nanomedical Sciences, Centre for Nanoscience and Nanotechnology, School of Bio and Chemical Engineering, Sathyabama Institute of Science and Technology, Chennai-600119, Tamil Nadu, India
4 shared publicationsRamar Thangam
Proteomics and Molecular Cell Physiology Laboratory, Department of Zoology, Bharathiar University, Coimbatore 641 046, TN, India; Department of Virology, King Institute of Preventive Medicine and Research, Guindy, Chennai 600 032, TN, India
4 shared publicationsKaruppaiya Vimala
Proteomics and Molecular Cell Physiology Laboratory, Department of Zoology, Bharathiar University, Coimbatore 641 046, TN, India
3 shared publicationsManickam Paulpandi
Proteomics & Molecular Cell Physiology Lab, Department of Zoology, Bharathiar University, Coimbatore-641 046, India
3 shared publicationsPalani Gunasekaran
3 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in Next Nanotechnology
- Vol. 10
Nanomedicine in human disease management: A comprehensive review of advances in diagnosis, targeted therapy, clinical translation, and future perspectives
- 10 July 2026
- Published by Elsevier in Next Nanotechnology
- Vol. 10
Open AccessNanomedicine in human disease management: A comprehensive review of advances in diagnosis, targeted therapy, clinical translation, and future perspectives
- Open Access
- 14 December 2022
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 134 (1)
Bioremediation of hexavalent chromium by transformation of Escherichia coli DH5α with chromate reductase (ChrR) genes of Pseudomonas putida isolated from tannery effluent
Hexavalent chromium (Cr(VI)), a toxic heavy metal, is a serious pollutant from tannery effluent, and its accumulation in soil and water causes severe environmental concerns and increasing public health issues. The present study focuses on the isolation and identification of chromium-reducing bacteria collected from the tannery industry in Dindigul, Tamil Nadu. Chromium-reducing bacteria Pseudomonas putida were identified by 16S rRNA sequencing followed by BLAST search. The plasmid with Cr(VI) reductase gene was isolated from Ps. putida and transferred to Escherichia coli DH5α for further studies. The bacterial cultures were kept under controlled conditions for 72 h to observe the growth rates and bacterial resistance to chromium. When strains wild-type and transformant E. coli DH5α were grown in chromium-supplemented media, they revealed significant growth, but strains cured type Ps. putida and E. coli DH5α recorded minimum growth. The Cr(VI) reduction employed by transformant E. coli DH5α and wild Ps. putida was 42.52 ± 1.48% and 44.46 ± 0.55%, respectively. The culture supernatant of the wild Ps. putida and transformant E. coli DH5α showed an increased reduction of Cr(VI) compared with cell extract supernatant and cell debris due to the extracellular activity of chromium reductase being responsible for Cr(VI) reduction. Besides, the chromium reductase gene was confirmed in the isolated Ps. putida and transformant E. coli DH5α. Transformant bacteria could employ an alternative method for heavy metal detoxification in contaminated environments like tannery effluent and mining processes. High Cr(VI) concentration resistance and high Cr(VI) reducing the strain's ability make it suitable for bioremediation. These possible horizontal gene transfer events indicated in this study may have enabled transformant E. coli DH5α as a good candidate for reducing the heavy metal pollution.
- 14 December 2022
- Published by Oxford University Press (OUP) in Journal of Applied Microbiology
- Vol. 134 (1)
Open AccessBioremediation of hexavalent chromium by transformation of Escherichia coli DH5α with chromate reductase (ChrR) genes of Pseudomonas putida isolated from tannery effluent
Hexavalent chromium (Cr(VI)), a toxic heavy metal, is a serious pollutant from tannery effluent, and its accumulation in soil and water causes severe environmental concerns and increasing public health issues. The present study focuses on the isolation and identification of chromium-reducing bacteria collected from the tannery industry in Dindigul, Tamil Nadu. Chromium-reducing bacteria Pseudomonas putida were identified by 16S rRNA sequencing followed by BLAST search. The plasmid with Cr(VI) reductase gene was isolated from Ps. putida and transferred to Escherichia coli DH5α for further studies. The bacterial cultures were kept under controlled conditions for 72 h to observe the growth rates and bacterial resistance to chromium. When strains wild-type and transformant E. coli DH5α were grown in chromium-supplemented media, they revealed significant growth, but strains cured type Ps. putida and E. coli DH5α recorded minimum growth. The Cr(VI) reduction employed by transformant E. coli DH5α and wild Ps. putida was 42.52 ± 1.48% and 44.46 ± 0.55%, respectively. The culture supernatant of the wild Ps. putida and transformant E. coli DH5α showed an increased reduction of Cr(VI) compared with cell extract supernatant and cell debris due to the extracellular activity of chromium reductase being responsible for Cr(VI) reduction. Besides, the chromium reductase gene was confirmed in the isolated Ps. putida and transformant E. coli DH5α. Transformant bacteria could employ an alternative method for heavy metal detoxification in contaminated environments like tannery effluent and mining processes. High Cr(VI) concentration resistance and high Cr(VI) reducing the strain's ability make it suitable for bioremediation. These possible horizontal gene transfer events indicated in this study may have enabled transformant E. coli DH5α as a good candidate for reducing the heavy metal pollution.
- 11 August 2022
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Nano
- Vol. 9 (10) , 3809-3820
The UV-B protective effect of a SiO2 doped TiO2 thin film regulates pitx3 and sparc expression during embryonic development of zebrafish
SiO2@TiO2 thin film synthesis and their UV protective application in microorganisms and molecular response in the embryonic development of zebrafish were elucidated.
- 11 August 2022
- Published by Royal Society of Chemistry (RSC) in Environmental Science: Nano
- Vol. 9 (10) , 3809-3820
The UV-B protective effect of a SiO2 doped TiO2 thin film regulates pitx3 and sparc expression during embryonic development of zebrafish
SiO2@TiO2 thin film synthesis and their UV protective application in microorganisms and molecular response in the embryonic development of zebrafish were elucidated.
- Open Access
- 23 June 2022
- Published by IntechOpen
Methods of Protein Detection in Cancer for Diagnosis, Prognosis and Therapy
Emerging proteomic technologies offer new insight in the study of malignant tumor to identify protein biomarkers for early detection, stratification, prediction and monitoring of treatment, as well as to detect target molecules for therapy. The tumor protein biomarker is responsible for the regulation of the cell cycle to promote cell proliferation and resistance to cell death. Important technologies include ELISA, immunohistochemistry, flow cytometry, western blot, mass spectrometry, protein microarray, and microfluidics for the study of screening, protein profiling, identification, qualitative and quantitative analysis of differential expressed oncoproteins relative to cancer tissues, counterparts at different stages of the disease from preneoplasia to neoplasia. It can also provide a detailed description of identifying tissue-specific protein biomarkers and to analysis the modification of protein activity in cancer conditions. In this chapter, we discuss current and emerging protein assays for improving cancer diagnosis, including trends toward advances in assay miniaturization, improve sensitivity and specificity, time and cost-effective, and accuracy in detection and measurement of protein activity. However, information from these protein diagnostic technologies should be integrated to obtain the optimal information required for the clinical management of a patient.
- 23 June 2022
- Published by IntechOpen
Open AccessMethods of Protein Detection in Cancer for Diagnosis, Prognosis and Therapy
Emerging proteomic technologies offer new insight in the study of malignant tumor to identify protein biomarkers for early detection, stratification, prediction and monitoring of treatment, as well as to detect target molecules for therapy. The tumor protein biomarker is responsible for the regulation of the cell cycle to promote cell proliferation and resistance to cell death. Important technologies include ELISA, immunohistochemistry, flow cytometry, western blot, mass spectrometry, protein microarray, and microfluidics for the study of screening, protein profiling, identification, qualitative and quantitative analysis of differential expressed oncoproteins relative to cancer tissues, counterparts at different stages of the disease from preneoplasia to neoplasia. It can also provide a detailed description of identifying tissue-specific protein biomarkers and to analysis the modification of protein activity in cancer conditions. In this chapter, we discuss current and emerging protein assays for improving cancer diagnosis, including trends toward advances in assay miniaturization, improve sensitivity and specificity, time and cost-effective, and accuracy in detection and measurement of protein activity. However, information from these protein diagnostic technologies should be integrated to obtain the optimal information required for the clinical management of a patient.
- 21 March 2022
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 136, 212756
Green synthesis of multifunctional carbon quantum dots: An approach in cancer theranostics
- 21 March 2022
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 136, 212756
Green synthesis of multifunctional carbon quantum dots: An approach in cancer theranostics
- 1 September 2021
- Published by Elsevier in Science of The Total Environment
- Vol. 787, 147530
Bisphenol-A alters hematopoiesis through EGFR/ERK signaling to induce myeloblastic condition in zebrafish model
- 1 September 2021
- Published by Elsevier in Science of The Total Environment
- Vol. 787, 147530
Bisphenol-A alters hematopoiesis through EGFR/ERK signaling to induce myeloblastic condition in zebrafish model
- 19 December 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (1) , 385-399
Co-delivery of Diverse Therapeutic Compounds Using PEG–PLGA Nanoparticle Cargo against Drug-Resistant Bacteria: An Improved Anti-biofilm Strategy
Controlling biofilms of bacteria is a challenging aspect because of their drug resistance potentials against a range of antibiotics, demanding the development of active anti-biofilm agents. Rutin, a natural antioxidant and benzamide, a synthetic antibacterial agent are having several pharmacological and antibacterial abilities. Herein, we developed PEG-PLGA NPs that synergistically carried rutin and benzamide as drug candidates besides displaying therapeutic and anti-biofilm functions. These drug delivery NPs were synthesized by oil-in-water emulsion (O/W) solvent evaporation technique. The obtained NPs were characterized by UV-vis, FT-IR, SEM, TEM and DLS measurements. Confocal laser scanning microscopy was employed to evaluate the anti-biofilm capabilities against Staphylococcus aureus and Pseudomonas aeruginosa and further quantified the levels of residual biofilm constituents such as protein and exo-polysaccharide (EPS). Drug release experiments showed the controlled release of rutin-benzamide for several days. Antibacterial analyses showed that the minimum inhibitory concentration (MIC) of NPs was at least two times lower than that of the free drugs. RB-PEG-PLGA NPs revealed that they targeted biofilm forming bacteria through disruption of membrane and biofilm surface and was observed to be non-toxic when tested using human erythrocytes and human cell lines. In vivo evaluations in zebrafish showed that the NPs did not alter the antioxidant functions and histological features of tissues. On the basis of results obtained, it is substantiated that the rutin-benzamide loaded nanocarrier offers potential anti-biofilm therapy due to its high anti-biofilm activity and biocompatibility.
- 19 December 2019
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (1) , 385-399
Co-delivery of Diverse Therapeutic Compounds Using PEG–PLGA Nanoparticle Cargo against Drug-Resistant Bacteria: An Improved Anti-biofilm Strategy
Controlling biofilms of bacteria is a challenging aspect because of their drug resistance potentials against a range of antibiotics, demanding the development of active anti-biofilm agents. Rutin, a natural antioxidant and benzamide, a synthetic antibacterial agent are having several pharmacological and antibacterial abilities. Herein, we developed PEG-PLGA NPs that synergistically carried rutin and benzamide as drug candidates besides displaying therapeutic and anti-biofilm functions. These drug delivery NPs were synthesized by oil-in-water emulsion (O/W) solvent evaporation technique. The obtained NPs were characterized by UV-vis, FT-IR, SEM, TEM and DLS measurements. Confocal laser scanning microscopy was employed to evaluate the anti-biofilm capabilities against Staphylococcus aureus and Pseudomonas aeruginosa and further quantified the levels of residual biofilm constituents such as protein and exo-polysaccharide (EPS). Drug release experiments showed the controlled release of rutin-benzamide for several days. Antibacterial analyses showed that the minimum inhibitory concentration (MIC) of NPs was at least two times lower than that of the free drugs. RB-PEG-PLGA NPs revealed that they targeted biofilm forming bacteria through disruption of membrane and biofilm surface and was observed to be non-toxic when tested using human erythrocytes and human cell lines. In vivo evaluations in zebrafish showed that the NPs did not alter the antioxidant functions and histological features of tissues. On the basis of results obtained, it is substantiated that the rutin-benzamide loaded nanocarrier offers potential anti-biofilm therapy due to its high anti-biofilm activity and biocompatibility.
- 21 September 2017
- Published by Wiley in ChemistrySelect
- Vol. 2 (27) , 8524-8534
Peptide‐Conjugated Nano‐Drug Delivery System to Improve Synergistic Molecular Chemotherapy for Colon Carcinoma
The biofunctional significance of hollow mesoporous silica nanoparticles (HMSNs) could be used as nano‐reservoirs. Here in the β‐sitosterol loaded into the hollow core and the cisplatin substituted with the carboxylic group of poly lactic acid (PLA)‐ polyethylene glycol (PEG) on the pore walls of HMSNs. Subsequently, the tumour biomarker somatostatin peptide (3207‐86) conjugated to Methyl polyethylene glycol 2‐maleimide ethyl ether (Meo‐PEG‐Mal) for the selective targeting of tumour cells. The surface modified HMSNs enable the internalization of cisplatin via chlorine ion release, through the cleavage of the coordinated interaction. Further, the β sitosterol release is dependent on the discharge rate of cisplatin and the pH of the cell microenvironment. The engineered nano‐drug delivery system could be used to selectively target cancer cells and deliver multimodal therapeutic schemes for the treatment of colon cancer
- 21 September 2017
- Published by Wiley in ChemistrySelect
- Vol. 2 (27) , 8524-8534
Peptide‐Conjugated Nano‐Drug Delivery System to Improve Synergistic Molecular Chemotherapy for Colon Carcinoma
The biofunctional significance of hollow mesoporous silica nanoparticles (HMSNs) could be used as nano‐reservoirs. Here in the β‐sitosterol loaded into the hollow core and the cisplatin substituted with the carboxylic group of poly lactic acid (PLA)‐ polyethylene glycol (PEG) on the pore walls of HMSNs. Subsequently, the tumour biomarker somatostatin peptide (3207‐86) conjugated to Methyl polyethylene glycol 2‐maleimide ethyl ether (Meo‐PEG‐Mal) for the selective targeting of tumour cells. The surface modified HMSNs enable the internalization of cisplatin via chlorine ion release, through the cleavage of the coordinated interaction. Further, the β sitosterol release is dependent on the discharge rate of cisplatin and the pH of the cell microenvironment. The engineered nano‐drug delivery system could be used to selectively target cancer cells and deliver multimodal therapeutic schemes for the treatment of colon cancer
- 1 February 2017
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 488, 92-108
Synergistic effect of chemo-photothermal for breast cancer therapy using folic acid (FA) modified zinc oxide nanosheet
- 1 February 2017
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 488, 92-108
Synergistic effect of chemo-photothermal for breast cancer therapy using folic acid (FA) modified zinc oxide nanosheet
- 13 January 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (16) , 12209-12223
Theranostic potentials of multifunctional chitosan–silver–phycoerythrin nanocomposites against triple negative breast cancer cells
Study focused to the applications of nanocomposites with therapeutic and imaging functions against TNBC cells. The developed multifunctional nanocomposites exhibited cell imaging, cytotoxicity with apoptosis induction against cancer cells.
- 13 January 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (16) , 12209-12223
Theranostic potentials of multifunctional chitosan–silver–phycoerythrin nanocomposites against triple negative breast cancer cells
Study focused to the applications of nanocomposites with therapeutic and imaging functions against TNBC cells. The developed multifunctional nanocomposites exhibited cell imaging, cytotoxicity with apoptosis induction against cancer cells.